Side-by-side · Research reference

HGH 191AAvsHumanin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED0/75 cited

BAnimal-StrongHUMAN-REVIEWED14/52 cited

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

Humanin

Mitochondrial-Derived Peptide · Cytoprotective

24-AAPeptide lengthZhu 2022

mtDNAEncoded originZhu 2022 Shahzaib 2026

Bax/BimPrimary targetZhu 2022 Morris 2021

SQ · Experimental

01Mechanism of Action

Parameter

HGH 191AA

Humanin

Primary target

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022 Lue 2021

Pathway

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival

Downstream effect

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022 Lue 2021 Velentza 2024

Feedback intact?

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis

Origin

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022 Shahzaib 2026

Antibody development

Rare — <2% develop binding antibodies, typically non-neutralizing

Not reported in animal models

02Dosage Protocols

Parameter

HGH 191AA

Humanin

Pediatric GHD

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

—

Adult GHD

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

—

Turner syndrome

0.045–0.050 mg/kg/day SQ

—

Idiopathic short stature

0.037 mg/kg/day SQ

—

AIDS wasting

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

—

Frequency

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Daily (IP)

Evidence basis

FDA-approved / decades of RCT data

Animal models (rat, mouse)Huang 2025 El 2022 Velentza 2024

Monitoring

IGF-1, glucose, thyroid function, bone age (children)

—

Duration

Years (children until epiphyseal closure); indefinite (adult GHD)

8–12 weeks in animal studies

Standard experimental dose (HNG)

—

4 mg/kg IP (rat)

Most common dose in rodent models.

Ex vivo bone culture

—

1 µg/mL

Protective against venetoclax-induced bone growth retardation.

Human data

—

None — no clinical trials reported

Analog (HNG)

—

Gly[14]-humanin — more potent variant

Substitution at position 14 enhances cytoprotective activity.

03Metabolic / Fat Loss Evidence

Parameter

HGH 191AA

Humanin

Primary fat target

Visceral and subcutaneous adipose tissue

—

Mechanism

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

—

Effect on lean mass

Significant lean mass increase (protein synthesis, nitrogen retention)

—

Insulin sensitivity

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

—

IGF-1 elevation

Dose-dependent, significant — primary anabolic mediator

—

Glucose metabolism

Hyperglycemia risk, especially high doses (AIDS wasting)

—

Body composition

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

—

Clinical context

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

—

Direct fat loss evidence

—

None

Mechanism overlap

—

Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect

04Side Effects & Safety

Parameter

HGH 191AA

Humanin

Injection site reaction

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

Not reported in animal studies (IP route)

Fluid retention / Edema

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

—

Glucose intolerance

Hyperglycemia, new-onset diabetes (anti-insulin effect)

—

Intracranial hypertension

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

—

Slipped capital femoral epiphysis

SCFE risk in children — limp, hip/knee pain (requires surgery)

—

Scoliosis progression

Rapid growth may unmask/progress scoliosis (monitor spine in children)

—

Hypothyroidism

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

—

Cancer risk

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

—

Antibody formation

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

—

Pancreatitis

Rare. Higher risk in children with certain syndromes (Prader-Willi).

—

Gynecomastia

Adolescent males (physiological during puberty, may be exacerbated)

—

Animal model safety

—

Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks

Human safety data

—

None — no clinical trials

Theoretical fibrillation risk

—

Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.

Reproductive safety

—

Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025

Absolute Contraindications

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

Humanin

·Unknown — no human data

Relative Contraindications

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

Humanin

·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)

05Administration Protocol

Parameter

HGH 191AA

Humanin

1. Reconstitution (if lyophilized)

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.

2. Injection site

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.

3. Timing

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

Daily administration in animal studies. Optimal timing not characterized.

4. Storage

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.

5. Needle

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

No FDA approval, no IND, no clinical trials. Experimental research tool only.

6. Monitoring

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

—

06Stack Synergy

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms

Humanin

+ MOTS-c

Multi-pathway

View MOTS-c →

Both are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.

Humanin: 4 mg/kg IP · daily (animal model)
MOTS-c: 5 mg/kg IP · daily (animal model)
Frequency: Once daily
Primary benefit: Mitochondrial health, metabolic efficiency, anti-apoptotic signaling